Ftse Mib
37.582,05
0,00%
DAX
22.034,13
0,00%
S&P 500
6.068,50
0,03%
NASDAQ
19.643,86
-0,36%
Bitcoin
96.202,51
0,47%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pasithea Therapeutics Corporation (KTTA) Pasithea Therapeutics Corporation (KTTA) Notizie

KTTA

Pasithea Therapeutics (KTTA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KTTA
DataOraFonteTitoloSimboloCompagnia
06/02/202501:15AllPennyStocks.comBig Mid-Week Move From This Small BiotechNASDAQ:KTTAPasithea Therapeutics Corporation
05/02/202512:59GlobeNewswire Inc.Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNASDAQ:KTTAPasithea Therapeutics Corporation
14/01/202514:02GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4NASDAQ:KTTAPasithea Therapeutics Corporation
27/09/202400:44GlobeNewswire Inc.Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:KTTAPasithea Therapeutics Corporation
26/09/202413:02GlobeNewswire Inc.Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced CancerNASDAQ:KTTAPasithea Therapeutics Corporation
09/09/202414:01GlobeNewswire Inc.Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity StudiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/09/202414:02GlobeNewswire Inc.Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardNASDAQ:KTTAPasithea Therapeutics Corporation
28/08/202415:11GlobeNewswire Inc.Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:KTTAPasithea Therapeutics Corporation
13/08/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTTAPasithea Therapeutics Corporation
13/06/202412:59GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAPasithea Therapeutics Corporation
28/05/202412:59GlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
29/04/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
24/04/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202403:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
13/02/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
18/01/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
08/01/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAPasithea Therapeutics Corporation
02/01/202414:35GlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323:00GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAPasithea Therapeutics Corporation
19/12/202323:19GlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
11/12/202314:01GlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202322:27GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202313:59GlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAPasithea Therapeutics Corporation
09/11/202313:59GlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323:01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
16/10/202323:18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202315:15Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202314:30GlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Final Results of Tender OfferNASDAQ:KTTAPasithea Therapeutics Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KTTA

La tua Cronologia

BIT
UC46D4
Unicredit Bank
BIT
P1JHP5
BNP Paribas Issuance
NASDAQ
CBXUX
Ci Canadian Equity Corpo...
TSXV
GMIN
G Mining Ventures
BIT
P1JTB0
BNP Paribas Issuance
BIT
XYLD
Xtrackers ESG USD Corpor...
BIT
GAMB
Gambero Rosso
TG
CZ43ZF
Commerzbank
TG
8UU
Marex
BIT
P1LDQ8
BNP Paribas Issuance
BIT
UB3JUU
UniCredit Bank
BIT
S29310
Societe Generale Effekten
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci